Product Description
Braintree Laboratories was developing bli-850, an oral drug, for the treatment of preparation in adult subjects undergoing colonoscopy with colon cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00756977)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Braintree Laboratories
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00756548 |
BLI850-302 | P3 |
Completed |
Colorectal Cancer |
2008-11-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT00756977 |
BLI850-301 | P3 |
Completed |
Colorectal Cancer |
2008-11-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|